For the first time in 12 years, gynecologists are rewriting the playbook on menopause.
New clinical guidance issued by the American College of Obstetricians and Gynecologists places hormone replacement therapy back at center stage for managing hot flashes, night sweats, and sleep loss. The shift comes as federal regulators dismantle safety warnings that shadowed these medications for more than two decades. For millions of women who endured debilitating symptoms in silence, the message from clinicians is blunt: you do not have to tough it out. "We would love our patients to go to their OB-GYNs regarding questions about menopause and really advocate for getting the treatment that they need," said Dr. Camille Clare, president of ACOG.
Biological menopause officially begins after a woman completes 12 consecutive months without a menstrual period—typically arriving around age 50. But the precursor phase, perimenopause, often wrecks daily routines long before bleeding stops. Estrogen and progesterone output drops sharply and erratically. The toll is steep. ACOG data reveals more than half of menopausal women suffer vasomotor disruptions like sudden hot flashes and night sweats. Two-thirds endure chronic sleep loss. And more than a third of perimenopausal and postmenopausal women globally experience depressive episodes. Yet many suffered quietly, deterred by decades of medical skepticism.
That hesitancy trace directly to 2002. A massive federal trial evaluating a combination pill of estrogen and progestin abruptly halted after findings linked the regimen to heightened risks of breast cancer and blood clots. Panic ensued. The Food and Drug Administration slapped boxed warnings on all hormone-based therapies, casting a 22-year chill over clinical practice. But follow-up trials altered the risk calculus, proving modern formulations—especially low-dose transdermal patches and gels—carry favorable benefit profiles for younger symptomatic women. Last year, the FDA struck boxed warnings off more than 20 pills, patches, and topical creams, and just cleared updated labeling for three additional estrogen patches.
Demand surged immediately. In response to localized distribution bottlenecks, pharmaceutical manufacturers doubled production capacity over the past year by adding factory shifts, prompting FDA officials to confirm that no nationwide supply collapse looms. "It’s undisputed that hormone therapy is the first line and most effective therapy for hot flashes," said Dr. Stephanie Faubion, medical director at The Menopause Society. Dr. JoAnn Manson, professor of medicine at Harvard Medical School, endorsed the shift, noting that systemic hormone therapy offers unmatched relief for moderate to severe symptoms when initiated before age 60 or within a decade of menopause onset.
Hormones, however, remain off-limits for patients with specific cancer histories or cardiovascular risks. For these women, clinicians highlighted new targeted alternatives. Fezolinetant, a newly approved compound, acts directly on temperature-regulating receptors in the brain to switch off hot flashes at the neurochemical source. A related agent, elinzanetant, operates through similar thermal pathways. In addition, doctors point to low-dose antidepressants to stabilize mood fluctuations, while localized vaginal estrogen creams provide relief for severe tissue dryness without flooding the bloodstream.
Patients experiencing persistent night sweats or sudden mood swings should schedule a dedicated consultation with their physician to evaluate their cardiovascular history, age, and symptom severity before settling on an intervention plan.